TTRX · Turn Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Abraham Chesed | ▲ Buy | Open Market | 1,447,268 Shares held | 10/23/2025 | View profile |
| Arthur F. Golden Director | ▼ Sell | Gift | 360,602 Shares held | 4/2/2026 | View profile |
| Bradley Evan Burnam Chief Executive Officer | ▼ Sell | Gift | 300,000 Shares held | 5/28/2026 | View profile |
| Martin William Dewhurst Director | ▲ Buy | Grant | 21,882 Shares held | 1/7/2026 | View profile |
| Zuraiz Chaudhary See Remarks | ▲ Buy | Open Market | 12,500 Shares held | 12/12/2025 | View profile |
| Neilesh Shailesh Ghodadra Chief Medical Officer | ▲ Buy | Grant | 10,000 Shares held | 10/8/2025 | View profile |
| Kent Edward Kester Director | ▲ Buy | Grant | 10,000 Shares held | 10/8/2025 | View profile |
| Andrew Gengos Director | ▲ Buy | Grant | 10,000 Shares held | 10/8/2025 | View profile |
Transaction History
| Bradley Evan Burnam | ▼ Sell | Gift | 300,000 | $0 | 5/28/2026 |
| Bradley Evan Burnam | ▼ Sell | Gift | 300,000 | $0 | 5/28/2026 |
| Bradley Evan Burnam | ▼ Sell | Gift | 300,000 | $0 | 5/28/2026 |
| Bradley Evan Burnam | ▼ Sell | Gift | 300,000 | $0 | 5/28/2026 |
| Bradley Evan Burnam | ▼ Sell | Gift | 300,000 | $0 | 4/2/2026 |
| Arthur F. Golden | ▼ Sell | Gift | 300,000 | $0 | 4/2/2026 |
| Martin William Dewhurst | ▲ Buy | Grant | 21,882 | $0 | 1/7/2026 |
| Zuraiz Chaudhary | ▲ Buy | Open Market | 2,500 | $9K | 12/12/2025 |
| Arthur F. Golden | ▲ Buy | Open Market | 9,868 | $34K | 11/24/2025 |
| Zuraiz Chaudhary | ▲ Buy | Open Market | 1,000 | $3K | 11/21/2025 |
| Arthur F. Golden | ▲ Buy | Open Market | 20,532 | $59K | 11/21/2025 |
| Zuraiz Chaudhary | ▲ Buy | Open Market | 1,450 | $4K | 11/20/2025 |
| Zuraiz Chaudhary | ▲ Buy | Open Market | 2,500 | $9K | 11/17/2025 |
| Abraham Chesed | ▲ Buy | Open Market | 14,286 | $66K | 10/23/2025 |
| Zuraiz Chaudhary | ▲ Buy | Open Market | 5,050 | $25K | 10/23/2025 |
| Arthur F. Golden | ▲ Buy | Open Market | 20,202 | $100K | 10/23/2025 |
| Arthur F. Golden | ▲ Buy | Grant | 10,000 | $0 | 10/8/2025 |
| Kent Edward Kester | ▲ Buy | Grant | 10,000 | $0 | 10/8/2025 |
| Neilesh Shailesh Ghodadra | ▲ Buy | Grant | 10,000 | $0 | 10/8/2025 |
| Andrew Gengos | ▲ Buy | Grant | 10,000 | $0 | 10/8/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Lucid Capital initiates coverage on TTRX with $24 target
Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.
Lucid Capital initiates coverage on TTRX with $24 target. Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.